Tariq Alrasheed

Dr. Tariq Alrasheed

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
YRYasmin Nasr Ramadan
Yasmin Nasr Ramadan
SASaleh F Alqifari
Saleh F Alqifari
KAKhaled Alshehri
Khaled Alshehri
AAAmirah Mohammad Alhowiti
Amirah Mohammad Alhowiti
HMHyder Mirghani
Hyder Mirghani
Helal HettaHelal Hetta
Helal Hetta
The current discovery that the gut microbiome, which contains roughly 100 trillion microbes, affects health and disease has catalyzed a boom in multidisciplinary research efforts focused on understanding this relationship. Also, it is commonly demonstrated that the gut and the CNS are closely related in a bidirectional pathway. A balanced gut microbiome is essential for regular brain activities and emotional responses. On the other hand, the CNS regulates the majority of GI physiology. Any disruption in this bidirectional pathway led to a progression of health problems in both directions, neurological and gastrointestinal diseases. In this review, we hope to shed light on the complicated connections of the microbiome-gut-brain axis and the critical roles of gut microbiome in the early development of the brain in order to get a deeper knowledge of microbiome-mediated pathological conditions and management options through rebalancing of gut microbiome.

7 January 2025 in Medicina
Verified
Journal Article
Open access
PDF file
IEImadeldin Elfaki
Imadeldin Elfaki
RMRashid Mir
Rashid Mir
MEMohamed E Elsir
Mohamed E Elsir
AHAbdullah Hamadi
Abdullah Hamadi
ZAZeyad M. Alharbi
Zeyad M. Alharbi
TMTurki Ahmed Muqri
Turki Ahmed Muqri
Metabolic syndrome is a metabolic disorder characterized by hypertension, dyslipidemia, impaired glucose tolerance, and abdominal obesity. Impaired insulin action or insulin resistance initiates metabolic syndrome. The prevalence of insulin resistance is increasing all over the world. Insulin resistance results in the defective metabolism of carbohydrates and lipids, in addition to low-grade chronic inflammation. Insulin resistance is associated with metabolic syndrome, which is a risk factor for a number of pathological conditions, such as Type 2 diabetes (T2D), cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), and polycystic ovarian syndrome (PCOS). Genome-wide association studies have increased our understanding of many loci linked to these diseases and others. In this review, we discuss insulin resistance and its contribution to metabolic syndrome and these diseases. We also discuss the genetic loci associated with them. Genetic testing is invaluable in the identification and stratification of susceptible populations and/or individuals. After susceptible individuals and/or populations have been identified via genetic testing or screening, lifestyle modifications such as regular exercise, weight loss, a healthy diet, and smoking cessation can reduce or prevent metabolic syndrome and its associated pathologies.

29 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Helal HettaHelal Hetta
Helal Hetta
SASaleh F Alqifari
Saleh F Alqifari
KAKhaled Alshehri
Khaled Alshehri
AAAmirah Mohammad Alhowiti
Amirah Mohammad Alhowiti
SASaud Alharbi
Saud Alharbi
Reem SayadReem Sayad
Reem Sayad
Background/Objectives: Anlotinib is a novel oral antiangiogenic tyrosine kinase inhibitor (TKI) approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC). However, its efficacy in combination with docetaxel remains incompletely understood. Given the need for effective second-line therapies after platinum-based chemotherapy, this systematic review aims to evaluate the therapeutic potential of anlotinib plus docetaxel in advanced NSCLC. Methods: The PubMed, WOS, Medline, and Scopus databases were screened for published articles up to 12 April 2024. We included RCTs comparing anlotinib plus docetaxel with docetaxel alone in advanced NSCLC after receiving platinum-based chemotherapy, reporting progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) as outcomes for both groups. Results: Our systematic review included three randomized controlled trials (RCTs) with a total of 151 patients in the anlotinib plus docetaxel group and 132 in the docetaxel-only group. Meta-analysis results demonstrated that the combination therapy significantly prolonged PFS (mean difference (MD) = 2.98, 95% confidence interval (CI), 1.95–4.00; p < 0.00001) and improved ORR (risk ratio (RR) = 3.04, 95% CI = 1.77–5.24; p < 0.00001). Additionally, the DCR was notably higher in the combination group (RR = 1.58, 95% CI = 1.34–1.87; p < 0.00001). Conclusions: Anlotinib plus docetaxel appears to be more effective as a second-line treatment of advanced NSCLC than docetaxel in prolonging PFS and increasing ORR and DCR.

28 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Helal HettaHelal Hetta
Helal Hetta
MAMostafa Ali
Mostafa Ali
SASaleh F Alqifari
Saleh F Alqifari
HSHoda Abdelaziz Salem
Hoda Abdelaziz Salem
KQKhulood A. Qasem
Khulood A. Qasem
Reem SayadReem Sayad
Reem Sayad
Background/Objectives: Non-small-cell lung cancer (NSCLC) frequently metastasizes to the brain, significantly impacting patient prognosis and quality of life. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in treating NSCLC with brain metastasis. So, we aimed to evaluate the clinical efficacy of anlotinib and various types of radiotherapy combinations used to treat NSCLC patients with brain metastasis regarding overall survival and the treatment of internal and external lesions. Methods: A comprehensive literature search was conducted in the databases PubMed, Scopus, WoS, MedLine, and Cochrane Library up to April 2024. Studies assessing the efficacy of anlotinib combined with whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), or other radiotherapy modalities in NSCLC patients with brain metastasis were included. The primary outcomes were (a) the efficacy of anlotinib and radiotherapy on the intracranial lesions and OS and (b) the effectiveness of combined anlotinib and radiotherapy versus radiotherapy alone in NSCLC patients with brain metastasis. The secondary outcome was the efficacy of anlotinib and radiotherapy on extracranial progression. We used a combination of keywords and MeSH terms including ‘non-small cell lung cancer’ OR ‘NSCLC’, ‘brain metastases’, ‘anlotinib’, ‘radiotherapy’, ‘radiation therapy’, and ‘combined treatment’, among others. Boolean operators (AND, OR) were applied as appropriate to optimize the search strategy across databases. Results: Nine studies met the inclusion criteria, comprising 210 patients in the combination group and 228 patients in the radiotherapy alone group. The combination of anlotinib with radiotherapy showed a significant improvement in iPFS compared to radiotherapy alone, with a pooled risk ratio (RR) for iORR of 1.18 (95% CI: 1.00–1.39) and a pooled SMD for OS of 0.03 (95% CI: −0.29, 0.36). Radiotherapy combined with anlotinib also demonstrated enhanced intracranial and extracranial control rates. Conclusions: Anlotinib combined with radiotherapy, especially WBRT, offers a promising treatment strategy for NSCLC patients with brain metastasis, improving intracranial control. Further large-scale randomized controlled trials are needed to confirm these findings and optimize treatment protocols.

16 January 2026 in Medicine
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
MAMansuor A. Alanazi
Mansuor A. Alanazi
AAAmirah M M Alatawi
Amirah M M Alatawi
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Gastrointestinal (GI) side effects from metformin often limit its use and can impact patient quality of life (QoL) and satisfaction. The extended-release (XR) formulation is thought to cause fewer GI adverse events than immediate-release (IR) metformin, potentially improving tolerability, treatment satisfaction, and adherence. To compare metformin IR vs XR in terms of GI tolerability (incidence of GI side effects), patient-reported QoL, and medication satisfaction over 6 months in Saudi patients with type 2 diabetes. In a prospective cohort of 119 newly diagnosed patients with type 2 diabetes (62 on IR, 57 on XR), we tracked GI adverse events using a standardized questionnaire at baseline and 6-month follow-up. Diabetes-specific QoL was measured with the diabetes therapy-related quality of life questionnaire (DTR-QOL), and treatment satisfaction was assessed with the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2). Metformin XR was associated with significantly better GI tolerability. By 6 months, 45.2% of IR patients and only 24.5% of XR patients reported any GI side effect ( P <.05). Rates of bothersome symptoms, such as diarrhea, were notably higher in the IR group. Patients on XR reported fewer interruptions of therapy due to GI upset. The DTR-QOL global score improved in both groups ( P <.05), but there was no significant difference in total DTR-QOL scores between groups ( P = .390). The OHA-Q ver. 2 global score improved in both groups ( P <.05), but the XR group had higher scores in domains related to satisfaction (median treatment satisfaction domain score 100 vs 77.78 for IR, P < .05), with a significant difference in OHA-Q ver. 2 global score (92.59 vs 86.31 for IR; P <.05). Metformin XR demonstrated superior GI tolerability, which translated into improved treatment satisfaction compared to IR. While the overall quality of life related to diabetes management improved similarly with both, the XR formulation reduced side effect burden, and the lower daily dosing led to higher patient-reported satisfaction. These findings support the use of metformin XR to enhance tolerability and adherence, potentially leading to improved long-term outcomes.

2 December 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
MZMOHAMMAD ZUBAIR
MOHAMMAD ZUBAIR
FFFarha Fatima
Farha Fatima
SRSUMBUL REHMAN
SUMBUL REHMAN
TATariq Alrasheed
Tariq Alrasheed
RARoba Alatawy
Roba Alatawy
MMM. Ahmad Mesaik
M. Ahmad Mesaik
Bacterial biofilms are closely associated with the rising threat of antimicrobial resistance, which is becoming a global concern. Recently, there has been increased interest in natural extracts as potential antimicrobial agents. One such extract is Dead Sea mud. While there is some evidence of its antimicrobial properties, it has not been extensively studied. Therefore, we designed a study to evaluate the potential of Dead Sea soil as an antimicrobial agent. For this purpose, three bacterial species (Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus) were isolated from the ulcerated foot of a patient in a hospital in Tabuk. P. aeruginosa exhibited significant antibiotic resistance, particularly to Levofloxacin (90%) and Tobramycin (80%), while S. aureus showed 70% resistance to Levofloxacin but no vancomycin resistance. Biofilm activity varied among bacterial strains, with P. aeruginosa showing 30% strong biofilm production. MIC values indicated resistance levels, with P. aeruginosa strain PA8 having the highest MIC at 650 µL/mL. All strains showed significant differences in exopolysaccharide (EPS) production at 0.25 × MIC (p ≤ 0.05) and 0.5 × MIC (p ≤ 0.005). Similarly, alginate production was significantly reduced at 0.25 × MIC (p ≤ 0.05), with even greater inhibition at 0.5 × MIC for combinations such as EC7 + SA5 (p ≤ 0.001). Hydrophobicity significantly changed at 0.25 × MIC (p ≤ 0.05), and combinations revealed highly significant reductions at 0.5 × MIC (p ≤ 0.001). Additionally, significant differences in outer membrane disruption were observed (p ≤ 0.05) with greater effects at 0.5 × MIC (p ≤ 0.005). Swarming motility was notably reduced for SA5 at 0.25 × MIC (p ≤ 0.05) and for PA2 at 0.5 × MIC (p ≤ 0.001). Chitinase activity showed greater reductions at 0.5 × MIC, with EC7 exhibiting the highest decrease. Lastly, sub-MIC concentrations enhanced reactive oxygen species (ROS) production, particularly for strains PA2 and SA5. Our results demonstrate the excellent potential of Dead Sea soil extract as an antimicrobial compound. Future studies should incorporate in vivo models to validate these findings clinically.